Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy
نویسندگان
چکیده
منابع مشابه
Recent Advances in Hodgkin Lymphoma
Hodgkin lymphoma (HL) is considered as a highly curable malignancy, but successful treatment can be associated with significant long-term toxicity [1]. Traditional treatment modalities include chemotherapy, radiotherapy (RT) and salvage chemotherapy with autologous stem cell transplantation (ASCT). The goal of modern treatment is focused on tailoring each patient’s approach according to age, ri...
متن کاملNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
There has been a recent emergence of novel targeted agents for treatment of Hodgkin and non-Hodgkin lymphoma. In particular, antibodies and antibody-drug conjugates directed against surface antigens, agents that block immune checkpoint pathways, and small molecule inhibitors directed against cell signaling pathways have shown significant promise in patients with relapsed and refractory disease ...
متن کاملTargeted therapy in relapsed classical hodgkin lymphoma.
Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients. Many patients with disease relapse can be successfully salvaged with second-line chemotherapy followed by autologous stem cell transplantation (ASCT). Patients whose disease relapses after ASCT a...
متن کاملRecent Advances in Hemophilia Gene Therapy
Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...
متن کاملRecent Advances in the Treatment of Non-Hodgkin Lymphoma
Non-Hodgkin lymphomas (NHLs) comprise a large and diverse group of malignancies of lymphoid origin. NHL is the fifth most commonly diagnosed cancer in both males and females. NHLs are divided into indolent and aggressive phenotypes, and can be further categorized into multiple histopathologic subtypes. Optimal therapy is critically dependent on the identification of the correct NHL subtype, as ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Oncology
سال: 2014
ISSN: 0368-2811,1465-3621
DOI: 10.1093/jjco/hyu204